We are international
Donate
TEXT SIZE   


A Phase I Study of Novel Proteasome Inhibitor PR-171 (carfilzomib)
By A. Keith Stewart, MD
12.17.06
A Phase I Study of Novel Proteasome Inhibitor PR-171 (carfilzomib) in Patients with Relapsed/Refractory Hematologic Malignancies



 related articles